News & Updates

Show Multimedia Only

Age-based ivermectin dosing safe, efficacious in children with scabies infection

24 Jun 2026 by

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.

Age-based ivermectin dosing safe, efficacious in children with scabies infection

24 Jun 2026

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

24 Jun 2026

Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

24 Jun 2026

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Switching between JAK inhibitors a feasible solution for severe alopecia areata

18 Jun 2026

Patients with treatment-refractory alopecia areata (AA) may benefit from switching between Janus kinase inhibitors (JAKis), suggests a study.

Switching between JAK inhibitors a feasible solution for severe alopecia areata

18 Jun 2026

$Lutikizumab shows promise in refractory hidradenitis suppurativa$

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 Jun 2026

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 Jun 2026

Dupilumab improves AD symptoms in adult Asians

06 Jun 2026 by

Treatment with dupilumab results in significant improvements in the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adult Asian patients without any serious adverse effects, a Singapore study has shown.

Dupilumab improves AD symptoms in adult Asians

06 Jun 2026

Isotretinoin use in adolescence does not compromise linear growth

30 May 2026

Treatment with isotretinoin for acne in adolescents does not appear to exert a negative effect on adult height, as reported in a study.

Isotretinoin use in adolescence does not compromise linear growth

30 May 2026

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026 by

Taking ixekizumab and tirzepatide together results in higher rates of skin clearance and weight loss compared with ixekizumab alone in patients with psoriasis and overweight or obesity, who represent a population that is difficult to treat, according to the phase IIIb TOGETHER-PsO trial.

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

27 May 2026

Are tests necessary for psoriasis patients treated with biologics?

25 May 2026

Many routine baseline screening and monitoring tests show no clear benefit to psoriasis patients prescribed biologic treatments, according to a study.

Are tests necessary for psoriasis patients treated with biologics?

25 May 2026

Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis

25 May 2026 by

The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.

Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis

25 May 2026

News & Updates

Showing Dermatology articles

Showing

Specialty:

Age-based ivermectin dosing safe, efficacious in children with scabies infection

Age-based ivermectin dosing safe, efficacious in children with scabies infection

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Switching between JAK inhibitors a feasible solution for severe alopecia areata

Switching between JAK inhibitors a feasible solution for severe alopecia areata

Lutikizumab shows promise in refractory hidradenitis suppurativa

Lutikizumab shows promise in refractory hidradenitis suppurativa

Dupilumab improves AD symptoms in adult Asians

Dupilumab improves AD symptoms in adult Asians

Isotretinoin use in adolescence does not compromise linear growth

Isotretinoin use in adolescence does not compromise linear growth

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

Ixekizumab plus tirzepatide confers multiple benefits in patients with psoriasis, high BMI

Are tests necessary for psoriasis patients treated with biologics?

Are tests necessary for psoriasis patients treated with biologics?

Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis

Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis